论文部分内容阅读
目的观察常规应用东菱迪芙防治血管常见疾病的疗效及安全性。方法于2002年3月～2007年3月对血管外科常见疾病309例常规应用东菱迪芙(巴曲酶注射液)予以降纤治疗,住院期间所有患者血浆纤堆蛋白原均控制在60～120mg/dl目标范围,记录患者对东菱迪芙产生的药物不良反应,以及用药前后血常规、凝血四项及血生化全项的变化。结果住院期间所有患者在用药过程中未发现明显的药物不良反应,没有观察到任何出血征兆;用药前后比较,血常规、凝血四项及生化全项各指标均未观察到有统计学意义的变化。结论东菱迪芙具有显著的降纤效果且使用安全可靠,建议针对临床合并高纤堆蛋白原血症的患者可以常规应用东菱迪芙行降纤治疗,从而有利于患者康复。
Objective To observe the curative effect and safety of routine application of Donglingdufu on common diseases of blood vessels. Methods From March 2002 to March 2007, 309 patients with common diseases of vascular surgery were treated with Donglingdufu (Batroxobin injection) for fibrinolytic therapy. Plasma fibrinogen in all patients was controlled at 60 ~ 120mg / dl target range, record the patient’s adverse reactions to the drug Donglingdi Fu, as well as before and after treatment of blood, blood clotting and blood biochemical changes in all items. Results No significant adverse drug reactions were observed in all patients during the course of hospitalization, and no signs of bleeding were observed. Before and after treatment, no statistically significant changes were observed in all four indexes of blood, coagulation and biochemistry . Conclusion Donglingdufu has a significant effect of lowering the fiber and safe and reliable, it is recommended for patients with clinical hyperfibrin in patients with conventional fibrinolytic treatment of Donglingdi Fu, which is conducive to patient rehabilitation.